Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Pelthos Therapeutics Inc.

PTHS · NYSE · CIK 0001919246 · Healthcare · Biotechnology

INSIDER SIGNAL

53.5 / 100

1 buyers · 2 purchase transaction lines · $999.8K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+16.8 / 25
Role+20.0 / 20
Recency+1.2 / 10
Conviction+8.5 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Friedberg Ezra MDirector
○▼▼▼
Francis Knuettel IICFO, Treas & Secty
○▼
Pauls MatthewDirector
▼▼
Greenleaf PeterDirector
▼▼
Davis Todd CDirector
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Davis Todd C · $999.8K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-06-11–2026-06-11

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

53.5 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 53.7
  2. 53.7
  3. 53.6
  4. 53.5
  5. 53.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
24Sales
4Other Form 4 lines
17SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING12 sale line(s) · context only
OTHER2 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-8.6%
3M
-21.9%
6M
-9.2%
12M
-24.5%

Volatility & liquidity

Volatility
145.7%
Beta
—
Avg daily value
USD 1.2M

Valuation

Market cap
USD 78.5M
P/E
—

Fundamentals

Profit margin
-257.9%
ROE
-111.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-10 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
104,573
Previous report
93,741
Avg daily volume
25,686
Days to cover
4.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-11Davis Todd CPurchase (P)Common Stock35,948USD 27.81USD 999,822SEC filing ↗
2024-09-13Francis Knuettel IIPurchase (P)Common Stock3,500USD 0.97USD 3,395SEC filing ↗
2024-09-12Malamut RichardPurchase (P)Common Stock10,400USD 0.94USD 9,776SEC filing ↗
2024-09-12Francis Knuettel IIPurchase (P)Common Stock1,700USD 0.97USD 1,649SEC filing ↗
2024-09-11Francis Knuettel IIPurchase (P)Common Stock5,500USD 0.94USD 5,170SEC filing ↗
2024-09-10Francis Knuettel IIPurchase (P)Common Stock6,500USD 0.89USD 5,785SEC filing ↗
2024-02-21Friedberg Ezra MPurchase (P)Common Stock16,667USD 6.00USD 100,002SEC filing ↗

Form 4 evidence

30 transaction lines in the latest 365-day window; 47 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Pauls MatthewSale (S)Common Stock786USD 21.00USD 16,506SEC filing ↗
2026-10-02Greenleaf PeterSale (S)Common Stock797USD 21.17USD 16,872SEC filing ↗
2026-10-02Friedberg Ezra MSale (S)Common Stock558USD 20.72USD 11,560SEC filing ↗
Show recent Form 4 evidence (18 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Pauls MatthewSale (S)Common Stock786USD 21.00USD 16,506SEC filing ↗
2026-10-02Greenleaf PeterSale (S)Common Stock797USD 21.17USD 16,872SEC filing ↗
2026-10-02Friedberg Ezra MSale (S)Common Stock558USD 20.72USD 11,560SEC filing ↗
2026-07-02Pauls MatthewSale (S)Common Stock786USD 26.16USD 20,564SEC filing ↗
2026-07-02Greenleaf PeterSale (S)Common Stock797USD 26.14USD 20,830SEC filing ↗
2026-07-02Friedberg Ezra MSale (S)Common Stock558USD 26.09USD 14,556SEC filing ↗
2026-06-15Friedberg Ezra MSale (S)Common Stock283USD 27.29USD 7,723SEC filing ↗
2026-06-11Davis Todd CPurchase (P)Common Stock35,948USD 27.81USD 999,822SEC filing ↗
2026-05-22Francis Knuettel IISale (S)Common Stock1,500USD 26.84USD 40,260SEC filing ↗
2026-05-22Francis Knuettel IID (D)Common Stock13,947USD 0.00USD 0SEC filing ↗
2026-05-14Friedberg Ezra MTax withholding (F)Common Stock144USD 27.01USD 3,889SEC filing ↗
2026-04-02Pauls MatthewSale (S)Common Stock786USD 20.92USD 16,440SEC filing ↗
2026-04-02Malamut RichardSale (S)Common Stock590USD 20.91USD 12,339SEC filing ↗
2026-04-02Greenleaf PeterSale (S)Common Stock797USD 20.92USD 16,671SEC filing ↗
2026-04-02Friedberg Ezra MSale (S)Common Stock558USD 20.91USD 11,670SEC filing ↗
2025-12-23Einhorn Andrew J.Award / grant (A)Common Stock12,000USD —USD —SEC filing ↗
2025-12-10Pauls MatthewGift (G)Common Stock9,542USD 0.00USD 0SEC filing ↗
2025-11-25Friedberg Ezra MSale (S)Common Stock10,000USD 28.03USD 280,300SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPTHS
CIK0001919246
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNYSE

Data coverage

Local Form 4 history47 transaction lines from 2024-02-21 to 2026-10-02
8 P purchase lines · 24 S sale lines · 15 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.